-
Something wrong with this record ?
Alternative splicing and mutation status of CHEK2 in stage III breast cancer
V Staalesen, J Falck, S Geisler, J Bartkova, AL Borresen-Dale, J Lukas, JR Lillehaug, J Bartek, PE Lonning
Language English Country England, Great Britain
NLK
Free Medical Journals
from 1997 to 2004
ProQuest Central
from 2000-01-01 to 1 year ago
Open Access Digital Library
from 1997-01-01
Medline Complete (EBSCOhost)
from 1997-01-09 to 2015-11-26
Health & Medicine (ProQuest)
from 2000-01-01 to 1 year ago
Public Health Database (ProQuest)
from 2000-01-01 to 1 year ago
PubMed
15361853
Knihovny.cz E-resources
- MeSH
- Alternative Splicing * MeSH
- Checkpoint Kinase 2 MeSH
- Immunohistochemistry MeSH
- Humans MeSH
- Molecular Sequence Data MeSH
- Mutation * MeSH
- DNA Mutational Analysis MeSH
- Breast Neoplasms * genetics metabolism MeSH
- Polymerase Chain Reaction MeSH
- Protein Serine-Threonine Kinases * genetics metabolism MeSH
- Base Sequence MeSH
- Check Tag
- Humans MeSH
- Female MeSH
The DNA damage checkpoint kinase, CHK2, promotes growth arrest or apoptosis through phosphorylating targets such as Cdc25A, Cdc25C, BRCA1, and p53. Both germline and somatic loss-of-function CHEK2 mutations occur in human tumours, the former linked to the Li-Fraumeni syndrome, and the latter found in diverse types of sporadic malignancies. Here we examined the status of CHK2 by genetic and immunohistochemical analyses in 53 breast carcinomas previously characterized for TP53 status. We identified two CHEK2 mutants, 470T>C (Ile157Thr), and a novel mutation, 1368insA leading to a premature stop codon in exon 13. The truncated protein encoded by CHEK2 carrying the 1368insA was stable yet mislocalized to the cytoplasm in tumour sections and when ectopically expressed in cultured cells. Unexpectedly, we found CHEK2 to be subject to extensive alternative splicing, with some 90 splice variants detected in our tumour series. While all cancers expressed normal-length CHEK2 mRNA together with the spliced transcripts, we demonstrate and/or predict some of these splice variants to lack CHK2 function and/or localize aberrantly. We conclude that cytoplasmic sequestration may represent a novel mechanism to disable CHK2, and propose to further explore the significance of the complex splicing patterns of this tumour suppressor gene in oncogenesis.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14079627
- 003
- CZ-PrNML
- 005
- 20141119213253.0
- 007
- ta
- 008
- 141119s2004 enk f 000 0|eng||
- 009
- AR
- 035 __
- $a (PubMed)15361853
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Staalesen, V. $u Department of Molecular Biology, University of Bergen, Bergen, Norway.
- 245 10
- $a Alternative splicing and mutation status of CHEK2 in stage III breast cancer / $c V Staalesen, J Falck, S Geisler, J Bartkova, AL Borresen-Dale, J Lukas, JR Lillehaug, J Bartek, PE Lonning
- 520 9_
- $a The DNA damage checkpoint kinase, CHK2, promotes growth arrest or apoptosis through phosphorylating targets such as Cdc25A, Cdc25C, BRCA1, and p53. Both germline and somatic loss-of-function CHEK2 mutations occur in human tumours, the former linked to the Li-Fraumeni syndrome, and the latter found in diverse types of sporadic malignancies. Here we examined the status of CHK2 by genetic and immunohistochemical analyses in 53 breast carcinomas previously characterized for TP53 status. We identified two CHEK2 mutants, 470T>C (Ile157Thr), and a novel mutation, 1368insA leading to a premature stop codon in exon 13. The truncated protein encoded by CHEK2 carrying the 1368insA was stable yet mislocalized to the cytoplasm in tumour sections and when ectopically expressed in cultured cells. Unexpectedly, we found CHEK2 to be subject to extensive alternative splicing, with some 90 splice variants detected in our tumour series. While all cancers expressed normal-length CHEK2 mRNA together with the spliced transcripts, we demonstrate and/or predict some of these splice variants to lack CHK2 function and/or localize aberrantly. We conclude that cytoplasmic sequestration may represent a novel mechanism to disable CHK2, and propose to further explore the significance of the complex splicing patterns of this tumour suppressor gene in oncogenesis.
- 590 __
- $a bohemika - dle Pubmed
- 650 12
- $a alternativní sestřih $7 D017398
- 650 02
- $a sekvence nukleotidů $7 D001483
- 650 12
- $a nádory prsu $x genetika $x metabolismus $7 D001943
- 650 02
- $a checkpoint kinasa 2 $7 D064447
- 650 02
- $a mutační analýza DNA $7 D004252
- 650 02
- $a ženské pohlaví $7 D005260
- 650 02
- $a lidé $7 D006801
- 650 02
- $a imunohistochemie $7 D007150
- 650 02
- $a molekulární sekvence - údaje $7 D008969
- 650 12
- $a mutace $7 D009154
- 650 02
- $a polymerázová řetězová reakce $7 D016133
- 650 12
- $a protein-serin-threoninkinasy $x genetika $x metabolismus $7 D017346
- 700 1_
- $a Falck, J.
- 700 1_
- $a Geisler, S.
- 700 1_
- $a Bártková, Jiřina $7 xx0094304
- 700 1_
- $a Borresen-Dale, A.L.
- 700 1_
- $a Lukáš, Jiří $7 xx0094305
- 700 1_
- $a Lillehaug, J.R.
- 700 1_
- $a Bártek, Jiří, $d 1953- $7 xx0046271
- 700 1_
- $a Lonning, P.E.
- 773 0_
- $t Oncogene $x 0950-9232 $g Roč. 23, č. 52 (2004), s. 8535-8544 $p Oncogene $w MED00003600
- 773 0_
- $p Oncogene $g 23(52):8535-44, 2004 Nov 4 $x 0950-9232
- 910 __
- $a ABA008 $y 4 $z 0
- 990 __
- $a 20141119213332 $b ABA008
- 991 __
- $a 20141119213332 $b ABA008
- 999 __
- $a ok $b bmc $g 1047962 $s 878646
- BAS __
- $a 3
- BMC __
- $a 2004 $b 23 $c 52 $d 8535-8544 $x MED00003600 $i 0950-9232 $m Oncogene $n Oncogene
- LZP __
- $a NLK 2014-1/lp